ReGenX Biosciences developed a gene therapy for Hunter syndrome, and the FDA requested longer-term pivotal results.
1 report, 1 independent
Updated Sep 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ReGenX Biosciences developed a gene therapy for Hunter syndrome, and the FDA requested longer-term pivotal results.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- ReGenX Biosciences submitted data to the FDA in response to a request for longer-term pivotal results for its gene therapy.Sub-event
FDA requested longer-term pivotal results for ReGenX's gene therapy for Hunter syndrome.1 source
Keep exploring
The entities involved
- FDA
-
ReGenX Biosciences (United States)
company in Washington D.C., United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- BenzingaRegenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date On Friday, REGENXBIO Inc. (NASDAQ:RGNX) shared new data from the Phase 1/2/3 CAMPSIITE trial of clemidsogene lanparv